Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Abir Salwa Ali; Malin Grönberg; Seppo W Langer; Morten Ladekarl; Geir Olav Hjortland; Lene Weber Vestermark; Pia Österlund; Staffan Welin; Henning Grønbæk; Ulrich Knigge; Halfdan Sorbye; Eva Tiensuu Janson

doi:10.1007/s12032-018-1103-x

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Abir Salwa Ali, Malin Grönberg, Seppo W Langer, Morten Ladekarl, Geir Olav Hjortland, Lene Weber Vestermark, Pia Österlund, Staffan Welin, Henning Grønbæk, Ulrich Knigge, Halfdan Sorbye, Eva Tiensuu Janson

Institut for Klinisk Medicin

6 Citationer (Scopus)

23 Downloads (Pure)

Abstract

High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.

Originalsprog	Engelsk
Artikelnummer	47
Tidsskrift	Medical Oncology
Vol/bind	35
Udgave nummer	4
Sider (fra-til)	1-7
Antal sider	7
ISSN	1357-0560
DOI	https://doi.org/10.1007/s12032-018-1103-x
Status	Udgivet - 1 apr. 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1007/s12032-018-1103-xLicens: CC BY

Ali2018_Article_IntravenousVersusOralEtoposideForlagets udgivne version, 877 KBLicens: CC BY

Citationsformater

Ali, A. S., Grönberg, M., Langer, S. W., Ladekarl, M., Hjortland, G. O., Vestermark, L. W., Österlund, P., Welin, S., Grønbæk, H., Knigge, U., Sorbye, H., & Janson, E. T. (2018). Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology, 35(4), 1-7. [47]. https://doi.org/10.1007/s12032-018-1103-x

Intravenous versus oral etoposide : efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). / Ali, Abir Salwa; Grönberg, Malin; Langer, Seppo W et al.

I: Medical Oncology, Bind 35, Nr. 4, 47, 01.04.2018, s. 1-7.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Ali, AS, Grönberg, M, Langer, SW, Ladekarl, M, Hjortland, GO, Vestermark, LW, Österlund, P, Welin, S, Grønbæk, H, Knigge, U, Sorbye, H & Janson, ET 2018, 'Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)', Medical Oncology, bind 35, nr. 4, 47, s. 1-7. https://doi.org/10.1007/s12032-018-1103-x

@article{e47e775adf654e1e8caaeba62bd23014,

title = "Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)",

abstract = "High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.",

keywords = "Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Phytogenic/administration & dosage, Disease-Free Survival, Etoposide/administration & dosage, Female, Humans, Infusions, Intravenous, Intestinal Neoplasms/drug therapy, Kaplan-Meier Estimate, Male, Middle Aged, Neuroendocrine Tumors/drug therapy, Pancreatic Neoplasms/drug therapy, Proportional Hazards Models, Retrospective Studies, Stomach Neoplasms/drug therapy, Treatment Outcome",

author = "Ali, {Abir Salwa} and Malin Gr{\"o}nberg and Langer, {Seppo W} and Morten Ladekarl and Hjortland, {Geir Olav} and Vestermark, {Lene Weber} and Pia {\"O}sterlund and Staffan Welin and Henning Gr{\o}nb{\ae}k and Ulrich Knigge and Halfdan Sorbye and Janson, {Eva Tiensuu}",

year = "2018",

month = apr,

day = "1",

doi = "10.1007/s12032-018-1103-x",

language = "English",

volume = "35",

pages = "1--7",

journal = "Medical Oncology",

issn = "1357-0560",

publisher = "Humana Press",

number = "4",

}

TY - JOUR

T1 - Intravenous versus oral etoposide

T2 - efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

AU - Ali, Abir Salwa

AU - Grönberg, Malin

AU - Langer, Seppo W

AU - Ladekarl, Morten

AU - Hjortland, Geir Olav

AU - Vestermark, Lene Weber

AU - Österlund, Pia

AU - Welin, Staffan

AU - Grønbæk, Henning

AU - Knigge, Ulrich

AU - Sorbye, Halfdan

AU - Janson, Eva Tiensuu

PY - 2018/4/1

Y1 - 2018/4/1

N2 - High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.

AB - High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs, G3) are aggressive cancers of the digestive system with poor prognosis and survival. Platinum-based chemotherapy (cisplatin/carboplatin + etoposide) is considered the first-line palliative treatment. Etoposide is frequently administered intravenously; however, oral etoposide may be used as an alternative. Concerns for oral etoposide include decreased bioavailability, inter- and intra-patient variability and patient compliance. We aimed to evaluate possible differences in progression-free survival (PFS) and overall survival (OS) in patients treated with oral etoposide compared to etoposide given as infusion. Patients (n = 236) from the Nordic NEC study were divided into three groups receiving etoposide as a long infusion (24 h, n = 170), short infusion (≤ 5 h, n = 33) or oral etoposide (n = 33) according to hospital tradition. PFS and OS were analyzed with Kaplan-Meier (log-rank), cox proportional hazard ratios and confidence intervals. No statistical differences were observed in PFS or OS when comparing patients receiving long infusion (median PFS 3.8 months, median OS 14.5 months), short infusion (PFS 5.6 months, OS 11.0 months) or oral etoposide (PFS 5.4 months, OS 11.3 months). We observed equal efficacy for the three administration routes suggesting oral etoposide may be safe and efficient in treating high-grade GEP-NEN, G3 patients scheduled for cisplatin/carboplatin + etoposide therapy.

KW - Administration, Oral

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Agents, Phytogenic/administration & dosage

KW - Disease-Free Survival

KW - Etoposide/administration & dosage

KW - Female

KW - Humans

KW - Infusions, Intravenous

KW - Intestinal Neoplasms/drug therapy

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Neuroendocrine Tumors/drug therapy

KW - Pancreatic Neoplasms/drug therapy

KW - Proportional Hazards Models

KW - Retrospective Studies

KW - Stomach Neoplasms/drug therapy

KW - Treatment Outcome

U2 - 10.1007/s12032-018-1103-x

DO - 10.1007/s12032-018-1103-x

M3 - Journal article

C2 - 29511910

SN - 1357-0560

VL - 35

SP - 1

EP - 7

JO - Medical Oncology

JF - Medical Oncology

IS - 4

M1 - 47

ER -

Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater